Navigation Links
JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
Date:1/30/2008

Mayo clinic in key role in treatment discovery

MELBOURNE, Australia, Jan. 30 /PRNewswire/ -- Australian and New York based company Cytopia Limited (ASX: CYT) announced today that its lead JAK2 inhibitor compound CYT387 has demonstrated potent activity in cells isolated from patients with myeloproliferative disorders (MPDs).

MPDs are a series of diseases where there is over-production of particular cells within the blood stream. One of these conditions is polycythemia vera (PV) where patients have excess production of red blood cells in the body which can lead to life-threatening conditions such as hemorrhage, thrombotic events (eg stroke) and enlargement of the spleen.

There are few pharmaceutical treatments for MPD patients and consequent unmet clinical need. Progressive disease can lead MPD patients to develop leukemia or myelofibrosis.

Over 95% of patients with PV and about 50% of patients with two related MPDs, essential thrombocythemia and primary myelofibrosis, possess a genetic mutation which causes over-activation of the enzyme JAK2. Cytopia is developing selective and potent inhibitors of the JAK2 enzyme to block excessive activity.

Cytopia has collaborated with leading laboratories in this field including the Royal North Shore Hospital in Sydney, Australia and the Mayo Clinic in Cleveland, USA to study the effects of its JAK2 inhibitors in pre-clinical studies on MPD patient cells.

The data obtained in these studies show that Cytopia's compounds block the mutant JAK2 enzyme and thereby inhibit, in the case of PV, the over-production of red blood cells. Additionally, when normal human cells were tested in the same assay, Cytopia's JAK2 inhibitor showed a possible therapeutic window with a greater potency inhibition of disease cells. Extensive screening against a panel of 73 kinase enzymes indicates that CYT387 possesses selectivity for JAK2, potentially minimizing off-target toxicity.

Dr Pardanani of the Mayo clinic said: "In ex vivo studies, we have seen encouraging preliminary results with Cytopia's compounds including the inhibition of erythroid colony growth from PV patients harboring the JAK2 V617F mutation."

Cytopia's Research Director Dr Chris Burns stated: "This data is important validation that our selective JAK2 inhibitors stop the proliferation of mutant cells from patients with these diseases at clinically achievable doses."

Cytopia is developing JAK2 inhibitors for the treatment of MPDs and other solid and blood cancers. In addition, other inhibitors of JAK2 are under development for cardiovascular and ophthalmic diseases.

About Cytopia

Cytopia Ltd is an Australian headquartered biotechnology company focused on the discovery and development of new drugs to treat cancer. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

http://www.cytopia.com.au

Relevant Links:

http://www.mpdfoundation.org

http://www.mpd-oz.org


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
4. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
5. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
8. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
9. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
10. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
11. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):